drugset / Trial / NCT07053306
SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
Phase 1
Recruiting
29 enrolled
The University of Texas Health Science Center at San Antonio
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
NaSingle-groupOpen-labelBasic science
Summary
To examine the 2-HIT hypothesis that the SGLT2i-induced stimulation of EGP, lipolysis, and ketone production requires the combination of volume depletion plus insulinopenia in T2D individuals.
Timeline
- Start
- 2025-04-29
- Primary completion
- 2027-06-01
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 25 mg | Oral |